electroacupuncture-orchestrates-intestinal-flora-remodeling-step

Electroacupuncture Orchestrates Intestinal Flora Remodeling: A Step Forward in Alleviating High Salt-Induced Vasculopathy

This study aims to investigate the therapeutic potential and mechanisms of electroacupuncture (EA) in alleviating vascular dysfunction caused by high-salt ...

Chengdu University of Traditional Chinese Medicine

Hyperlipidemia is a metabolic disease characterized by elevated levels of blood lipids and lipoproteins and a major pathogenic factor of atherosclerosis. In China, Erchen decoction (ECD) has been widely used to treat hyperlipidemia. However, there is no systematic review found. In order to evaluate the efficacy and safety of ECD in the treatment of hyperlipidemia, we need to conduct a meta-analysis and systematic evaluation.

Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis.

Chronic gastritis is a very common chronic gastric mucosal inflammatory disease in China. Long-term chronic inflammation will aggravate the disease and develop towards gastric cancer. Clinically, infection with Helicobacter pylori (H pylori) is a common cause. The application of antibiotics to eradicate H pylori has been reported to have produced drug resistance. However, the application of Shengyang Yiwei Decoction(SYD) in traditional Chinese medicine has resulted in significant clinical effects and small side effects. It is used for the treatment of chronic gastritis and other diseases, but there is a lack of systematic reviews on the treatment of chronic gastritis by SYD. This article reviews the efficacy and safety of SYD in the treatment of chronic gastritis.

Shengyang Yiwei Decoction for the treatment of chronic gastritis: A protocol for a systematic review and meta-analysis.

Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome characterized by excessive deposition of fat in hepatocytes except for alcohol and other specific hepatic factors. Xiaochaihu decoction (XD) has been widely used to treat NAFLD in China. However, there is no systematic review found. In order to evaluate the efficacy and safety of XD in the treatment of NAFLS, we need to conduct a meta-analysis and systematic evaluation.

Xiaochaihu decoction for nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis.

Nonalcoholic fatty liver disease (NAFLD) is considered to be a manifestation of hepatic metabolic syndrome. Some studies on the pathogenesis of NAFLD by targeting gut microbiota have attracted wide attention. Previous studies have demonstrated the positive effects of berberine and evodiamine on metabolic diseases and gut microbiota dysbiosis. However, it is not known whether the combination of berberine and evodiamine (BE) can prevent the development of high-fat diet (HFD)-induced NAFLD. Therefore, we aimed to explore the protective effects of BE on the development of HFD-induced NAFLD from the perspective of the gut microbiota. Gut microbiota profiles were established by high throughput sequencing of the bacterial 16S ribosomal RNA gene. The effects of BE on liver and intestinal tissue, intestinal barrier integrity, and hepatic inflammation were also investigated. The results showed that the abundance and diversity of gut microbiota were enriched by BE treatment, with an increase in beneficial bacteria, such as Lactobacillus, Ruminococcus, and Prevotella, and a decrease in pathogenic bacteria such as Fusobacterium and Lachnospira. In addition, BE effectively improved liver fat accumulation and tissue damage, inhibited the apoptosis of intestinal epithelial cells, increased the contents of intestinal tight junction proteins, and decreased the expression of pro-inflammatory factors. Consequently, BE treatment could be an effective and alternative strategy for alleviating NAFLD by modulating gut microbiota and safeguarding the intestinal barrier.

The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats.

Berberine has been widely used for the adjuvant therapy of several cardiovascular diseases (CVDs). However, evidence for its efficacy remains controversial.

Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials.

Non-alcoholic fatty liver disease (NAFLD) represents a global health challenge. Berberine, an isoquinoline alkaloid traditionally used for metabolic disorders, has garnered attention for its potential therapeutic interventions.

Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research.

Article	Year
Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis. Medicine\| PubMed ID: 33080674	2020
Shengyang Yiwei Decoction for the treatment of chronic gastritis: A protocol for a systematic review and meta-analysis. Medicine\| PubMed ID: 33120827	2020
Xiaochaihu decoction for nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis. Medicine\| PubMed ID: 33761728	2021
The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica\| PubMed ID: 35584453	2022
Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine : international journal of phytotherapy and phytopharmacology\| PubMed ID: 36805484	2023
Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research. Frontiers in pharmacology\| PubMed ID: 40949129	2025

Wenyu Zhu

Biography

JoVE Journal Publications

Other Publications